Tags

Type your tag names separated by a space and hit enter

Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers.
PLoS One. 2015; 10(10):e0139233.Plos

Abstract

To assess the value of exosomal miRNAs as biomarkers for Alzheimer disease (AD), the expression of microRNAs was measured in a plasma fraction enriched in exosomes by differential centrifugation, using Illumina deep sequencing. Samples from 35 persons with a clinical diagnosis of AD dementia were compared to 35 age and sex matched controls. Although these samples contained less than 0.1 microgram of total RNA, deep sequencing gave reliable and informative results. Twenty miRNAs showed significant differences in the AD group in initial screening (miR-23b-3p, miR-24-3p, miR-29b-3p, miR-125b-5p, miR-138-5p, miR-139-5p, miR-141-3p, miR-150-5p, miR-152-3p, miR-185-5p, miR-338-3p, miR-342-3p, miR-342-5p, miR-548at-5p, miR-659-5p, miR-3065-5p, miR-3613-3p, miR-3916, miR-4772-3p, miR-5001-3p), many of which satisfied additional biological and statistical criteria, and among which a panel of seven miRNAs were highly informative in a machine learning model for predicting AD status of individual samples with 83-89% accuracy. This performance is not due to over-fitting, because a) we used separate samples for training and testing, and b) similar performance was achieved when tested on technical replicate data. Perhaps the most interesting single miRNA was miR-342-3p, which was a) expressed in the AD group at about 60% of control levels, b) highly correlated with several of the other miRNAs that were significantly down-regulated in AD, and c) was also reported to be down-regulated in AD in two previous studies. The findings warrant replication and follow-up with a larger cohort of patients and controls who have been carefully characterized in terms of cognitive and imaging data, other biomarkers (e.g., CSF amyloid and tau levels) and risk factors (e.g., apoE4 status), and who are sampled repeatedly over time. Integrating miRNA expression data with other data is likely to provide informative and robust biomarkers in Alzheimer disease.

Links

PMC Free PDF

Authors+Show Affiliations

Lugli G
Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Cohen AM
Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America.
Bennett DA
Rush Alzheimer's Disease Center, Rush University, Chicago, Illinois, United States of America.
Shah RC
Rush Alzheimer's Disease Center, Rush University, Chicago, Illinois, United States of America.
Fields CJ
HPCBio, University of Illinois, Urbana, Illinois, United States of America.
Hernandez AG
Roy J. Carver Biotechnology Center, Urbana, Illinois, United States of America.
Smalheiser NR
Department of Psychiatry and Psychiatric Institute, University of Illinois at Chicago, Chicago, Illinois, United States of America.

MeSH

Alzheimer DiseaseAnimalsBiomarkers, TumorCase-Control StudiesExosomesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansMaleMiceMicroRNAsPlasma

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26426747

Citation

Lugli, Giovanni, et al. "Plasma Exosomal miRNAs in Persons With and Without Alzheimer Disease: Altered Expression and Prospects for Biomarkers." PloS One, vol. 10, no. 10, 2015, pp. e0139233.
Lugli G, Cohen AM, Bennett DA, et al. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One. 2015;10(10):e0139233.
Lugli, G., Cohen, A. M., Bennett, D. A., Shah, R. C., Fields, C. J., Hernandez, A. G., & Smalheiser, N. R. (2015). Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PloS One, 10(10), e0139233. https://doi.org/10.1371/journal.pone.0139233
Lugli G, et al. Plasma Exosomal miRNAs in Persons With and Without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One. 2015;10(10):e0139233. PubMed PMID: 26426747.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. AU - Lugli,Giovanni, AU - Cohen,Aaron M, AU - Bennett,David A, AU - Shah,Raj C, AU - Fields,Christopher J, AU - Hernandez,Alvaro G, AU - Smalheiser,Neil R, Y1 - 2015/10/01/ PY - 2015/06/10/received PY - 2015/09/10/accepted PY - 2015/10/2/entrez PY - 2015/10/2/pubmed PY - 2016/6/1/medline SP - e0139233 EP - e0139233 JF - PloS one JO - PLoS One VL - 10 IS - 10 N2 - To assess the value of exosomal miRNAs as biomarkers for Alzheimer disease (AD), the expression of microRNAs was measured in a plasma fraction enriched in exosomes by differential centrifugation, using Illumina deep sequencing. Samples from 35 persons with a clinical diagnosis of AD dementia were compared to 35 age and sex matched controls. Although these samples contained less than 0.1 microgram of total RNA, deep sequencing gave reliable and informative results. Twenty miRNAs showed significant differences in the AD group in initial screening (miR-23b-3p, miR-24-3p, miR-29b-3p, miR-125b-5p, miR-138-5p, miR-139-5p, miR-141-3p, miR-150-5p, miR-152-3p, miR-185-5p, miR-338-3p, miR-342-3p, miR-342-5p, miR-548at-5p, miR-659-5p, miR-3065-5p, miR-3613-3p, miR-3916, miR-4772-3p, miR-5001-3p), many of which satisfied additional biological and statistical criteria, and among which a panel of seven miRNAs were highly informative in a machine learning model for predicting AD status of individual samples with 83-89% accuracy. This performance is not due to over-fitting, because a) we used separate samples for training and testing, and b) similar performance was achieved when tested on technical replicate data. Perhaps the most interesting single miRNA was miR-342-3p, which was a) expressed in the AD group at about 60% of control levels, b) highly correlated with several of the other miRNAs that were significantly down-regulated in AD, and c) was also reported to be down-regulated in AD in two previous studies. The findings warrant replication and follow-up with a larger cohort of patients and controls who have been carefully characterized in terms of cognitive and imaging data, other biomarkers (e.g., CSF amyloid and tau levels) and risk factors (e.g., apoE4 status), and who are sampled repeatedly over time. Integrating miRNA expression data with other data is likely to provide informative and robust biomarkers in Alzheimer disease. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/26426747/Plasma_Exosomal_miRNAs_in_Persons_with_and_without_Alzheimer_Disease:_Altered_Expression_and_Prospects_for_Biomarkers_ DB - PRIME DP - Unbound Medicine ER -